Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

LUPUSCARE

Financiado

Cerrado

PRECISION CARE IN SYSTEMIC AUTOIMMUNITY AN INTEGRATED MULTI TISSUE LEVEL APPROA...

PRECISION CARE IN SYSTEMIC AUTOIMMUNITY AN INTEGRATED MULTI TISSUE LEVEL APPROACH FOR SYSTEMIC LUPUS ERYTHEMATOSUS SLE Systemic lupus erythematosus (SLE) is a heterogeneous disease whereby an interplay of environmental, genetic and epigenetic factors lead to perturbation of complex biological networks culminating into diverse clinical phenotypes o... ver más

31/08/2023

BIOMEDICAL RESEARC...

2M€

Presupuesto del proyecto: 2M€

Líder del proyecto

IDRYMA IATROVIOLOGIKON EREUNON AKADEMIAS ATHI... No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Fecha límite participación Sin fecha límite de participación.

Ver 2 Participantes

Financiación concedida El organismo H2020 notifico la concesión del proyecto el día 2023-08-31

ERC-2016-ADG: ERC Advanced Grant

I+D

Cerrada hace 8 años

0% 100% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

2 Participantes

BIOMEDICAL RESEARCH FOUNDATI...

2.36M€ | Lider

EDERTEK SCOOP

263.66K€ | Participante

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

PRECISESADS Molecular Reclassification to Find Clinically Useful Biomark... 23M€ Cerrado

GENETICS OF SLE Genetics of Systemic lupus erythematosus in northern and sou... 173K€ Cerrado

RTC-2015-3562-1 Desarrollo y Validación clínica de un sistema de análisis de... 49K€ Cerrado

EARLINESS Early and sensitive detection of renal involvement and treat... 226K€ Cerrado

PRECISESADS Molecular Reclassification to Find Clinically Useful Biomark... 23M€ Cerrado

ClarifyLupus Launching the Breakthrough in Lupus Diagnostics 71K€ Cerrado

Duración del proyecto: 72 meses Fecha Inicio: 2017-08-24
Fecha Fin: 2023-08-31

Líder del proyecto

IDRYMA IATROVIOLOGIKON EREUNON AKADEMIAS ATHI... No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 2M€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto Systemic lupus erythematosus (SLE) is a heterogeneous disease whereby an interplay of environmental, genetic and epigenetic factors lead to perturbation of complex biological networks culminating into diverse clinical phenotypes of varying severity. High throughput methods have allowed an initial glimpse into pathogenesis and have laid the foundations for a molecular-based taxonomy for personalized therapy. Based on our experience with the molecular characterization of SLE, a recently completed RNA sequencing analysis of 150 patients, and our track- record of paradigm shift trials in SLE, we will integrate data from multi-tissue analyses with novel technologies to improve its diagnosis, monitoring and therapy, and ask fundamental pathogenetic questions in systemic autoimmunity. More specifically, we will design gene expression panels and expression profile/clinical trait correlation matrices for diagnostics, personalized immunotherapy and improved clinical trial design. In a systematic multi-tissue approach, we will examine the role of somatic mutations in enhancing immune hyperactivity and the risk for lymphoma. The staggering (7-9:1) female predominance will be elucidated through elaborate genomic, epigenomic and microbiota analyses of family trios. Finally, we will be pursuing the innovative hypothesis that the fundamental abnormalities of SLE lie within the bone marrow hematopoietic stem cells (HSCs) - from which all cells that participate in the pathogenesis of SLE originate - and establish it as a unifying pathogenetic mechanism. By a combination of novel experimental analyses with single cell genomics, multi–omics, humanized animal models, genome editing and an organ on-a-chip device, we will validate HSCs as a therapeutic target. The utility of SLE research extends beyond its boundaries, by providing unique insights as to how the immune system recognizes self-constituents and maintains its homeostasis, and how gender impacts on disease biology.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores